Biotinylated Human Claudin-18.2 Full Length Protein (VLP)

用户评价
货号-规格
价格
Qty.
CL2-H82P3-20ug
¥5250.00
CL2-H82P3-100ug
¥10500.00
CL2-H82P3-500ug (250ug X 2)
询价
合计0件 产品金额¥ 0

产品详情

  • 应用说明(Application)

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • 分子别名(Synonyms)

    Claudin-18.2, CLDN18, Claudin-18

  • 表达区间及表达系统(Source)

    Biotinylated Human Claudin-18.2 Full Length Protein (VLP) (CL2-H82P3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Val 261 (Accession # P56856-2 ).

    Predicted N-terminus: Met 1

  • 蛋白结构(Molecular Characterization)

    *The isotype control of empty/mock VLP (Cat. No. VLP-N82P3) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • 标记(Labeling)

    The VLP is biotinylated with propriety technology.

  • 蛋白标记度(Protein Ratio)

    Passed as determined by the HABA assay / binding ELISA.

  • 纯度(Purity)

    >95% as determined by SEC-HPLC.

  • 制剂(Formulation)

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 运输(Shipping)

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • 存储(Storage)

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • SEC-HPLC

    Claudin-18.2 SEC-HPLC

    The purity of Biotinylated Human Claudin-18.2 Full Length Protein (VLP) (Cat. No. CL2-H82P3) was greater than 95% as determined by SEC-HPLC.

  • 活性(Bioactivity)-ELISA

     Claudin-18.2 ELISA

    Immobilized Biotinylated Human Claudin-18.2 Full Length Protein (VLP) (Cat. No. CL2-H82P3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-Claudin-18.2 antibody with a linear range of 0.05-2 ng/mL (QC tested).

    Protocol
  •  Claudin-18.2 ELISA

    ELISA comparison of biotinylated human Claudin-18.2 (virus-like particles) using anti-Claudin-18.2 antibody shows ACRO (Cat. No. CL2-H82P3) has superior bioactivity to Company K (Routinely tested).

    Protocol
  • 活性(Bioactivity)-SPR

     Claudin-18.2 SPR

    Biotinylated Human Claudin-18.2 Full Length Protein (VLP) (Cat. No. CL2-H82P3) immobilized on SA Chip can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with an affinity constant of 0.601 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • 均一性(Identity)-DLS

     Claudin-18.2 DLS

    The mean peak Radius of VLP is 60-85 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

用户评价
发表评论

背景介绍

A tight junction protein normally confined to gastric mucosa but exposed on tumor cell surfaces during malignant transformation. It is a premier target in gastric and pancreatic adenocarcinoma, with the monoclonal antibody zolbetuximab demonstrating significant survival benefit in CLDN18.2-positive advanced disease.

前沿进展

 
药物研发进展
  • 英文全称:

    Claudin-18 splice variant 2

  • 中文全称:

    密蛋白-18剪接变体2

  • 种类:

  • 上市药物数量:

    1 详情

  • 临床药物数量:

    69 详情

  • 最高研发阶段:

    临床三期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍